Alpha particle emitting isotopes are of considerable interest for radionuclide therapy because of their high cytotoxicity and short path length. Due to the relatively high availability, 
Introduction
Alpha-particle-emitting radionuclides have several physical characteristics that make them attractive for radionuclide therapy. The emitted a particles are much heavier than other subatomic particles emitted from decaying radionuclides and thus they have a much shorter range in tissues. The high linear energy transfer of a particles induces signicantly more DNA double strand breaks than do b-particles.
1 Furthermore, the relative biological effectiveness of a particles does not depend on hypoxia or cell cycle considerations.
2 There are only a few a particle emitting radionuclides that have properties suitable for developing therapeutic radiopharmaceuticals: generatorobtained 212 212 Bi, 213 Bi and 226 Th short half-lives oen limit the application of these radionuclides to situations when the tumour cells are rapidly accessible to the targeting agent. Crucial for radiopharmaceuticals stability are bifunctional ligands which can be attached to the targeting biomolecules and can bind a radioactive metal cation rapidly and selectively. The targeted a-radionuclide therapy (TAT), in particular, requires a very stable attachment of the radionuclide to the carrier molecule, because unbound a-emitters may target healthy tissues, thus leading also to the irradiation of healthy organs. In the case of 225 Ac, 223 Ra and 227 Th the designed ligand must form chemically stable complexes both with the parent and also with the decay radionuclides. 225 Ac decays directly to 221 Fr (alkali metal), which has a half-life of 4.9 minutes, and escapes from 225 Ac-radiobioconjugates. Similar situation appears in the case of 227 Th and 223 Ra where the decay product, the gaseous 219 Rn is easily liberated from 227 Th and 223 Ra radiobioconjugates. Till now only 223 Ra in the simple form of RaCl 2 , with its natural affinity to build into bones, as does calcium, nds application in the treatment of bone metastases from breast and prostate cancers. 3 Additionally, current supplies of medically useful a-emitters remain limited by isolated by-products from nuclear weapons processing and power plants development within the USA and Soviet Union, where the parental stock is preserved for disposal. Actually, only three sources are available for obtaining "clinical grade" 225 Ac ( 213 Bi):
Oak Ridge National Laboratory (USA), Institute of Physics and Power Engineering (Obninsk, Russia), and Institute for Transuranium Elements (Karlsruhe, Germany). The actual level of 225 Ac production ($1.7 Ci per year) is sufficient only for preclinical studies and for limited number of clinical trials. 4 Therefore, a cyclotron-produced 211 At seems to be the most promising candidate for TAT, because its 7.2 h half-life assures sufficient time for its transportation, synthetic chemistry, multistep labelling, quality control, and clinical application without problems caused by the relatively long-living daughters emitting a-particle. Another merit of this radionuclide is simplicity of its production in cyclotrons in the 209 Bi(a, 2n) 211 At nuclear reaction, followed by simple dry distillation and isolation from irradiated bismuth target.
Attaching 211 At to biomolecules targeting cancer cells is crucial for its application in the radionuclide therapy. Although astatine is generally treated as a halogen, it also shows a signicant metallic character in certain conditions. 5 The strength of aryl carbon-halogen bond for astatine is signi-cantly lower than that for iodine 6 which precludes the use of standard direct radio-iodination methods for labelling monoclonal antibodies (mAbs) with At have been reported. One from the recently developed approaches is based on application of small nanoparticles as vehicles for 211 At. Liposomes, spherical vesicles of lipid bilayers which can range from 100 to 800 nm in diameter, are the most widely used nanostructures for cancer therapy. 15 211 At-loaded liposomes were capable to deliver high doses of radiation to xenograed tumours in mice. 16 Hartman et al. 17 have developed single walled carbon nanotubes labelled with 211 AtCl, which was bonded by noncovalent van der Waals interactions within the interior side walls of the nanotubes. In another approach Kućka et al. 18 and Cędrowska et al. 19 used remarkable affinity of astatine towards metallic silver and proposed application of astatinated silver-containing particles coated with poly(ethylene oxide) for cancer therapy. Bochvarova et al. 20 and Wunderlich et al. 21 have found that elemental tellurium exhibits high affinity for astatine. In acidic and neutral solutions adsorption of 211 At on tellurium was complete. The 211 At adsorbed on Te grains was used to study therapeutic effect of a particles by injection of 211 At-Te grains directly into a tumour in the mouse model.
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It is well known that iodine has high affinity for the noble metal surface. The degree of specic adsorption of halides on the gold surface increases in the order F À < Cl À < Br À < I À , indicating the decreasing energy of a solvation of these species.
In particular, F À has the lowest affinity and only nonspecically or weakly specically adsorbs on the metal surface. At-AuNP-S-PEG-SP(5-11) radiobioconjugate, its stability studies in human serum (HS) and cerebrospinal uid (CSF) and toxicity to human glioma cells T98G.
Results and discussion
Although a large number of peptides, monoclonal antibodies and other molecules suitable for targeted radiotherapy have been developed, applying them in a cancer therapy is possible only when the radionuclide forms a stable bond with a biomolecule. This is particularly important in the case of a emitters, because highly toxic radionuclide released from radiobioconjugate may accumulate in critical organs. Due to the relatively high availability, 211 At is actually the most perspective a emitter for targeted therapy. However, many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking other 211 At labelling strategies.
Therefore, without a good chemical method of attaching 211 At to potential cancer targeting agents which will provide high in vivo stability of the formed conjugate, the application of this radionuclide in targeted radiotherapy will be limited. Herein, we have proposed an alternative method of labelling molecules with 211 At in order to solve stability problems of formed bioconjugates. The new method consists in the use of gold nanoparticles as a carrier for 211 At. Before labelling with 211 At, the AuNPs are modied with biomolecules in a simple way by using thiol-PEG linker. It is known that iodide is strongly adsorbed on noble metal surfaces such as Au, Pd and Pt forming strong surface covalent bond according to the reaction:
The determined by X-ray Photoelectron Spectroscopy (XPS) zero valency of both surface metal and adsorbed iodine atoms can only mean that iodine is covalently bonded to the metal surface. 31 We believe, that due to the similarity between iodine and astatine adsorption of 211 At undergoes according to the same reaction. Because of the increasing tendency of halides from F À to I À to form covalent bond with gold surface we expect that chemisorption of At will be the strongest in the halogen group. Therefore, in this paper we propose to use gold nanoparticles as prosthetic group for astatination. AuNPs, 5 and 15 nm median diameter, were synthesized by using sodium citrate and tannic acid as stabilizing agents.
Synthesized AuNPs are stable in solution because the citrate stopping layer of the AuNPs provides an electrostatic repulsion force resulting from the electric double layer.
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The biologically active fragment of Substance P(5-11), named shortly as SP (5) (6) (7) (8) (9) (10) (11) , was conjugated to the gold nanoparticles to obtain bioconjugates targeting NK1 receptors on glioma cells. Previously it was found that Substance P in cerebrospinal uid exhibits a stability of 84% aer 24 hours, while the serum residence time is only 1 to 2 minutes due to the rapid degradation. 33 We have also shown that SP(5-11) has similar affinity to NK1 receptors as the whole peptide (IC 50 ¼ 38 nM). 34 The PEG linker (2000 kDa) comprising the disulde bridge and the N-hydroxysuccinimide esters (NHS) at the ends was used for synthesis of the SP(5-11)-PEG-SS-PEG-SP(5-11) conjugate. The process of nanoparticles biofunctionalization is summarized in Fig. 1 .
The synthesized SP(5-11)-PEG-SS-PEG-SP(5-11) conjugates were spontaneously attached to the AuNPs surface. When the disulde bridge is disrupted sulphur atoms can be easily attached to the surface of gold nanoparticles to form stable Au-S bond. To calculate the number of SP(5-11) molecules attached to the AuNPs surface, we applied the gel ltration chromatography technique. As shown in and that 15 nm AuNP contains about 3300 molecules of SP(5-11) (4.7 molecules per nm 2 ). Taking into account that total surface area of 5 nm AuNP is 78.5 nm 2 and that the area occupied on Au by S atoms is 1. Fig. 3 . The transmission electron micrograph of AuNPs-S-PEG-Substance P (5) (6) (7) (8) (9) (10) (11) shows that the particles are uniformly dispersed with signicantly narrow size equal to 5 nm and to 15 nm (Fig. 3) . It was not possible to observe the "corona" around the gold nanoparticle due to poor interaction of the electron beam with the peptide molecules (low electron density), in contrast to the strong scattering of the electron beam when it interacted with metallic nanoparticles.
In order to additionally conrm the presence of SP(5-11) on the nanoparticles surface hydrodynamic diameters and zeta potentials of AuNPs, AuNP-S-PEG-CH 3 and AuNP-S-PEG-SP(5-11) were measured at pH 7 ( Table 1) . The particles size, determined by DLS, was signicantly larger than that observed by TEM. This is caused by fact that the DLS technique measures the mean hydrodynamic diameter of the AuNPs core bounded by the organic and solvation layers, and this hydrodynamic diameter is affected by the viscosity and concentration of the medium. TEM, however, gives the diameter of the core alone. The increase of the hydrodynamic diameter aer addition of polyethylene glycol (PEG) or a peptide is commonly observed aer coating nanoparticles with biomolecules, like it was in the case of AuNPs modied by folic acid.
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The difference between the zeta potential of citrate AuNPs and AuNP-S-PEG-SP(5-11) additionally conrms the surface modication. The negative zeta potential value of around À40 mV for AuNP-S-PEG-SP(5-11) conjugate indicates that the particles repel each other and that there is no tendency for the particles to aggregate as conrmed by monitoring changes in hydrodynamic diameter during 7 days.
The At radionuclides in water at pH ¼ 6 are shown in Table 2 . Also labelling efficiency in the solutions at pH 2 and 10 were performed. In all cases the labelling yield exceeded 99%, but in solutions of pH 2 and 10 the agglomeration of the nanoconjugates was observed. Therefore, further labelling of bioconjugates were conducted at pH 6.
The labelling yield of AuNPs with 211
At is much higher (>99%) than in the case of another commonly used prosthetic group N-succinimidyl-3-(tri-n-butylstannyl) benzoate where the labelling yield is between 60-70%. 36 For the boron precursor and for the Rh[16aneS4-diol] group the yields are equal to 80-89% (ref. 36 and 37) and 80%, 11 respectively. As presented in Table 2, the  211 At and   131 I absorption on AuNP-S-PEG-SP(5-11) At adsorption on AuNPs agree well with the prior reports of high affinity and strong binding of heavy halide ions to the noble metals surface. 23, 24 In the case of iodine radionuclides this specic adsorption is well documented in the eld of surface chemistry. In our work we have demonstrated for the rst time that astatine also forms strong bond with the gold surface.
Stability of 211 At-AuNP-S-PEG-SP(5-11) in human serum and in cerebrospinal uid was studied at different time points (Table 3 and At has shown that free 211 At does not bind to proteins present in both media. The radiobioconjugates were found to be very stable towards dissociation -almost no release of 211 At was observed during 24 h, corresponding to more than 3 half-lives. As shown in Tables 3 and 4 the astatinated radiobioconjugates exhibit better stability than the iodinated analogues. This conrms our assumption that astatine, as the biggest halogen in the group, forms strongest bond with Au surface. The in vitro studies were carried out on human gliomas tumour T98G cells overexpressing NK1 receptors on the cell membrane. At rst, the internalization of AuNP-S-PEG-SP(5- Atastatide. We also have measured cytotoxicity of non-radioactive AuNPs and AuNP-S-PEG-SP(5-11) bioconjugates in the function of concentration. Cells were treated with radioactivity for over 24 h and the metabolic activity was assessed by colorimetric MTT assay in comparison to non-treated cells, as presented in Fig. 6 and 7 .
In Fig. 6 and 7 data are presented as the average percent AE SD from three independent experiments (*denotes statistically signicant differences from unexposed control, P < 0.05). The obtained results demonstrate that 211 At-AuNPs(15 nm) and 211 At-AuNP(15 nm)-S-PEG SP(5-11) signicantly reduce At-astatide was also reducing the cell viability ($80%), although the level was not so spectacular as with the targeting vector (Fig. 6A) .
In the case of 211 At-AuNP(5 nm)-S-PEG-SP(5-11) (Fig. 7) cell viability (ca. 40%) was reached at dose around 800 kBq mL À1 , a dose higher than for radiolabelled AuNP(15 nm)-SP(5-11). This result is probably due to the much lower number of attached HS-PEG-SP(5-11) molecules on the surface of 5 nm compare to 15 nm nanoparticles. Performed cytotoxicity studies with the control probes of non-radioactive AuNPs and AuNP-S-PEG-SP(5-11) bioconjugate exhibited their almost non-toxic effect. The survived fraction of cells was high, equal to almost 88%, even aer exposure to concentration as high as 1 mg mL À1 (Fig. 5B) . It should be mentioned that amount of 211 At-AuNP-S-PEG-SP(5-11) carrier used in the cells studies was equal to 1 mg mL À1 concentration of the unlabeled AuNP-S-PEG-SP(5-11) bioconjugate; therefore, possible additional toxic effect from non-radioactive conjugate was negligible. As shown in Fig. 6 and 7 the cytotoxicity of 5 nm 211 At-AuNP-S-PEG-SP(5-11) was nearly the same as that of 15 nm 211 At-AuNP-S-PEG-SP(5-11) radiobioconjugate, indicating that the size of the radiolabelled nanoparticles does not affect the cytotoxicity of radiobioconjugate.
Conclusions
In this study we described new concept of the preparation of astatinated bioconjugates using the covalent adsorption of astatine atoms on the surface of gold nanoparticles. The conjugated probes were stable for 24 h in human serum and cerebrospinal uid. radiobioconjugate for glioma treatment is excluded, because of its relatively large size and high hydrophilicity, which prevent it from crossing the blood-brain barrier (BBB). The BBB is especially limited to larger molecules following systemic application. As mentioned by Cordier et al. cumulative organ toxicity using a emitter labelled targeting agents severely limit the systemic approach of gliomas. 25 These limitations have stimulated the development of strategies for local drug application. In cell studies the following materials were used: DMEM medium (Gibco, Poland), phosphate-buffered saline (PBS), dimethylsulfoxide (DMSO), 3-(4,5-dimetyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) from Sigma Aldrich, (Poland). Fetal calf serum was the product of Biological Industries (Israel). T98G cells were purchased from the American Type Tissue Culture Collection (ATCC, Rockville, MD) and maintained according to the ATCC protocol.
Experimental

Instrumentations
Shape, diameter and morphology of the nanoparticles and nanoparticle bioconjugates were determined by transmission electron microscopy (TEM, LEO 912B). The apparent hydrodynamic diameter and zeta potential (z) were measured by dynamic light scattering (DLS, Malvern, UK). The radioactivity of collected samples was measured with the gamma spectrometer containing germanium detector (Canberra, Meriden, CT, USA). The detector had a resolution of 0.8 at 5.9 keV, 1.0 at 123 keV and 1.9 at 1332 keV. Radioactivity of 211 At was quantied by its 89.69 keV g-ray.
The oxidation state of astatine ions was determined by paper electrophoresis (Sigma-Aldrich horizontal electrophoresis) on Whatman GF83 Glass Paper at the potential gradient 12 V cm À1 for 20 min with 0.01 M NaNO 3 as the electrolyte. Deionized water was prepared by the Hydrolab water purication system (Hydrolab, Poland).
TLC analyses were performed on Alufolien sheets RP-18 Merck 7.5 cm using MeOH as a developing solvent. The distribution of radioactivity on the paper electrophoresis or TLC sheets was measured by Storage Phosphor System Cyclone Plus (Perkin-Elmer Life and Analytical Sciences) and analyzed using Optiquant soware (version 5.0) provided by the manufacturer.
High-performance liquid chromatography (HPLC) was performed using the VWR-Hitachi LaChrom Elite HPLC system which consisted of a pump L2130, column thermostate L-2350, UV diode array detector (DAD) L-2455 and the EZChrom Elite data system. The radioactivity was monitored using a 3 Â 3 00 NaI(Tl) scintillation detector Raytest Gabi Star (Straubenhardt, Germany). The separation of SP(5-11)-PEG-SS-PEG-SP(5-11) from reaction mixture was accomplished on the LiChrospher® 100 RP-18 analytical column (5 mm particle size, 4.6 mm Â 250 mm) from Merck (Germany). The solvent and gradient conditions were as follows: solvent A 0.1% (v/v) triuoroacetic acid (TFA) in water, solvent B 0.1% (v/v) triuoro-acetic acid (TFA) in acetonitrile. System 1: 0% to 70% B in 0-15 min, 70% to 95% B in 15-20 min, 95% B in 20-30 min, 1 mL min À1 ; UV detection (220-400 nm). The identication and separation of Au nanoparticles decorated with (5-11)SP-PEG-SS-PEG-SP(5-11) were performed using aqueous gel ltration column Polysep-GFC-P-Linear (7.8 mm Â 300 mm) from Phenomenex (USA). Isocratic elution was performed at a ow rate of 0.5 mL min À1 using water (system 2).
Synthesis of 15 nm gold nanoparticles
Gold nanoparticles of 15 nm diameter were synthesized by the modied Turkevich method. 38 For this purpose 39.38 mg of gold(III) chloride trihydrate was dissolved in 100 mL of distilled water and heated under reux in round bottom ask. Next 111.79 mg of trisodium citrate dihydrate was dissolved in 10 mL of distilled water. During boiling the solution of gold(III) chloride trihydrate the whole amount of trisodium citrate dihydrate was added rapidly and the mixture was heated for additional 15 minutes. The cooled down ask with gold nanoparticles was wrapped with aluminium foil and stored at 4-8 C. Correctly prepared solution of gold nanoparticles with size 15 nm has the colour of red wine. The size of nanoparticles was checked by TEM and DLS techniques.
Synthesis of 5 nm gold nanoparticles
AuNPs with 5 nm diameter were synthesized in water by chemical reduction as described before. 39 Aqueous solution of chloroauric acid (93.80 g of 1.84 10 À2 wt%) was boiled, and next the mixture of sodium citrate (4.48 g, 0.877 wt%) and tannic acid (1.73 g, 1 wt%) was added. Following the addition of the mixture the solution color changed from yellow to dark red. The suspension was stirred for additional 15 min and cooled down to room temperature.
AuNP PEG functionalization
The synthesized 5 nm and 15 nm gold nanoparticles were coated with CH 3 -PEG-SH with average molar mass 800 at different molar ratios of PEG to gold nanoparticles in order to determine its effect on the labelling efficiency. The ratios were equal to 2500 : 1, 1500 : 1, 500 : 1 for AuNPs 15 nm and 50 : 1, 100 : 1, 200 : 1 for AuNPs 5 nm. The CH 3 -PEG-SH was mixed with nanoparticles and stirred for 24 h. The size and zeta potential of Au-PEG NPs were checked by DLS technique.
SP(5-11) solution was mixed with 200 mL of human serum (HS) or cerebrospinal uid (CSF) and incubated at room temperature. Stability studies were carried out aer 2 h, 4 h and 24 h on three analogous samples using the TLC technique. The blank tests with the HS or CSF and radionuclide solutions were carried out to estimate the percentage of possible binding of free 211 At to proteins present in both.
AuNPs and AuNPs-SP(5-11) internalization
The internalization studies were performed using AuNPs and AuNPs-SP (5) (6) (7) (8) (9) (10) (11) I-AuNPs-SP(5-11). Aer treatment, the growth medium of each well was collected, the cells were washed twice with 750 mL of PBS and incubated with 500 mL of pre-warmed trypsin solution at 37 C for 10 min. Subsequently, the cells were collected and activity of each fraction was measured. The results are expressed as a percentage of the total radioactivity added.
Cytotoxicity evaluation
The impact of AuNPs, AuNP-S-PEG-SP(5-11), free 211 At, 211 AtAuNP and 211 At-AuNP-S-PEG-SP(5-11) on metabolic activity and proliferation of T98G cells was measured by colorimetric MTT assay. The assay was performed as described. 40 In brief, T98G cells were seeded a day before an experiment in 96-well microplates (TPP) at a density of 4 Â 10 3 cells per well in 100 mL of culture medium. Next, cells were treated for 24 h with increasing concentration of the cold AuNPs and AuNP-S-PEG-SP(5-11) or with radiobioconjugate labelled with 211 At (1-800 kBq mL À1 ) or only with 211 At-astatide (1-800 kBq mL À1 ). Aer 24 h incubation, the cell culture medium was removed and 100 mL of 3 mg mL À1 MTT solution was added to each well. Aer 3 h incubation at 37 C the MTT solution was removed. Remaining insoluble formazan crystals were dissolved in 100 mL DMSO and absorbance of the solution was measured at 570 nm in the plate reader spectrophotometer Innite M200 (Tecan). At least three independent experiments in six replicate wells were conducted.
Statistical analysis
At least three independent experiments in six replicate wells were conducted for each toxicity point. Difference between samples and control were evaluated using GraphPad Prism 5.0 soware (GraphPad Soware Inc., USA). Toxicological data were evaluated by Kruskal-Wallis One Way Analysis of Variance on Ranks (ANOVA) followed by post hoc Dunnet's method. Differences were considered statistically signicant when the p-value was less than <0.05.
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